KaydedilenlerDerginizi ekleyin

Dergiler / Anatolian Journal of Emergency Medicine / 2026 / Cilt: 2 Sayı: 1

Opioid Antagonistlerinin Klinik Önemi ve Uygulama Yolları

Clinical Importance and Application Paths of Opioid Antagonists

Arzu Denizbaşı Altınok(MARMARA ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-4589-8251
Çiğdem Özpolat(MARMARA ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-4589-8251
Özge Onur(MARMARA ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-0110-3533
Sayfa
34–38
Yayın Tarihi
2019-03-31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bu derleme en son indikasyonlar ile opioid antagonistlerini n hastane içi veya dışı ndaki kullan ı mlar ı n ı özetlemek için yazı lm ış t ı r.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Opioid antagoni stleri yaln ı z kimyasal ve farmakolojik özellikler olarak değ il ayn ı zamanda klinik kullan ı mdaki etkinleri anlam ı nda da e şsiz bir ilaç grubudur.
📊
Temel Bulgular & Veri:Klinik etkinliğ ini ve populeritesi sonucu Naloksonun farkl ı ilaç formulasyonları geli ş tirilmi ş ve farkl ı Nalokson uygulamalar ı çalışı lm ış t ı r.
💡
Sonuç & Katkı:Bu derleme en son indikasyonlar ile opioid antagonistlerini n hastane içi veya dışı ndaki kullan ı mlar ı n ı özetlemek için yazı lm ış t ı r.
🔬Tür:Deneysel Tarla Denemesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Opioid Antagonist · Nalokson · Resusitasyon

Özet

Opioid antagoni stleri yaln ı z kimyasal ve farmakolojik özellikler olarak değ il ayn ı zamanda klinik kullan ı mdaki etkinleri anlam ı nda da e şsiz bir ilaç grubudur. Bu s ı n ıf içinde özellikle Nalokson yaygı n olarak kardiyopulmoner arrest vakalar ı nda opioid ile indüklenen solunum depresyonunu geriye döndürmek için kullan ı lmaktad ı r. Kan ı ta dayal ı t ı pta Nalokson uygulamalar ı önemli yer tutar. Klinik etkinliğ ini ve populeritesi sonucu Naloksonun farkl ı ilaç formulasyonları geli ş tirilmi ş ve farkl ı Nalokson uygulamalar ı çalışı lm ış t ı r. Nalokson intramüsküler, intranazal, subkutan, nebülize veya endotrakeal verilebilen bir ilaçtı r. Uygun doz ve konsantrasyonlar ilac ın verilme yoluna göre farklı l ı k gösterir. Bu derleme en son indikasyonlar ile opioid antagonistlerini n hastane içi veya dışı ndaki kullan ı mlar ı n ı özetlemek için yazı lm ış t ı r.

Abstract

Opioid antagonists are a unique class of drugs in terms of not only chemical and pharmacological properties but also efficiency in clinical practice. This class, namely Naloxone, is used widely to revert opioid induced respiratory depression in cardiopulmonary arrest cases. In evidence based medicine Naloxone administration is an important management. As a result of clinical effectiveness and popularity, different drug formulations of Naloxone have been developed and different Naloxone administrations have been studied. Naloxone is a drug that can be administered via intramuscular, intranasal, subcutaneous, inhalation or endotracheal routes. Appropriate dosing and concentration vary according to the route of administration. This review is written to summarize the use of opioid antagonists in in or out of hospital settings with recent indications.

🔖

Bu Makaleye Atıf Yap

Altınok, A. D., Özpolat, Ç., Onur, Ö. (2019). Opioid Antagonistlerinin Klinik Önemi ve Uygulama Yolları. Anatolian Journal of Emergency Medicine, Cilt: 2 Sayı: 1, 34–38. https://ajindex.com/articles/1361506

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (22)

  1. Goodman AJ, Le Bourdonnec B, Dolle RE. Mu opioid receptor antagonists: recent developments. Chem Med Chem. 2007, 2(11):1552–70.
  2. Straus MM, Ghitza UE, Tai B. Preventing deaths from rising opioid overdose in the US. Subst Abuse Rehab. 2013, 4: 65-72.
  3. Lucyk S, Nelson LS. Opioid receptor antagonists. Ed. Brent et al. Critical Care Toxicology. DOI 10.1007/978-3-319-17900-1-62. 2907-11.
  4. Levy JH, Brister NW, Shearin A, Ziegler J, et al. Wheal and flare responses to opioids in humans. Anesthesiology. 1989;70(5):756–60.
  5. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain. 1988;33(2):149–60.
  6. Mills CA, Flacke JW, Miller JD, Davis LJ, et al. Cardiovascular effects of fentanyl reversal by naloxone at varying arterial carbon dioxide tensions in dogs. Anesth Analg. 1988;67(8):730–6.
  7. Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–55.
  8. Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med. 1986;15(5):566–70.
  9. Kienbaum P, Thurauf N, Michel MC, Scherbaum N, et al. Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology. 1998;88(5):1154–61.
  10. Tenenbein M. Continuous naloxone infusion for opiate poisoning in infancy. J Pediatr. 1984;105(4):645–8. 9. Buchanan JF, Brown CR. ‘Designer drugs’. A problem in clinical toxicology. Med Toxicol Adverse Drug Exp. 1988;3(1):1–17.
  11. Kienbaum P, Thurauf N, Michel MC, Scherbaum N, et al. Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology. 1998;88(5):1154–61.
  12. Kienbaum P, Heuter T, Michel MC, Scherbaum N, et al. Sympathetic neural activation evoked by mu-receptor blockade in patients addicted to opioids is abolished by intravenous clonidine. Anesthesiology. 2002;96(2):346–51.
  13. Nelson LS, Howland MA. Opioid antagonists. In: Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR, editors. Goldfrank’s toxicological emergencies. 10th ed. New York: McGraw-Hill; 2015. p. 510–5.
  14. Elzey MJ, Fudin, Edwards ES. Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems. (2016): Expert Opinion on Drug Delivery, DOI: 10.1080/17425247.2017.1230097http://dx.doi.org/10.1080/17425247.2017.1230097
  15. Center for Drug Evaluation and Research. Summary review for regulatory action: Evzio. 2014 [cited 2016 May 25]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205787Orig1s000SumR.pdf FDA review of the approved naloxone auto-injector.
  16. Center for Drug Evaluation and Research. Summary review for regulatoryaction: Narcan. 2015 [cited 2016 May 25]. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM480092.pdf. FDA review of the approved naloxone nasal spray.
  17. Barton ED, Ramos J, Colwell C, et al. Intranasal administration of naloxone by paramedics. Prehosp Emerg Care. 2002;6:54–58.
  18. Barton ED, Colwell CB, Wolfe T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005;29:265–271.
  19. Kelly A-M, Kerr D, Dietze P, et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182:24–27.
  20. Kerr D, Kelly A-M, Dietze P, et al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104:2067–2074
  21. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23): 631-635 https://eccguidelines.heart.org/index.php/circulation/cpr-ecc-guidelines-2/part-10-special-circumstances-of-resuscitation/highlights-introduction/highlights/
  22. Elzey MJ, Fudin, Edwards ES. Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems. (2016): Expert Opinion on Drug Delivery, DOI: 10.1080/17425247.2017.1230097http://dx.doi.org/10.1080/17425247.2017.1230097